Gordon C. Jayson

22.6k total citations · 5 hit papers
257 papers, 14.0k citations indexed

About

Gordon C. Jayson is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Gordon C. Jayson has authored 257 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Molecular Biology, 82 papers in Reproductive Medicine and 81 papers in Oncology. Recurrent topics in Gordon C. Jayson's work include Ovarian cancer diagnosis and treatment (82 papers), Angiogenesis and VEGF in Cancer (51 papers) and Proteoglycans and glycosaminoglycans research (31 papers). Gordon C. Jayson is often cited by papers focused on Ovarian cancer diagnosis and treatment (82 papers), Angiogenesis and VEGF in Cancer (51 papers) and Proteoglycans and glycosaminoglycans research (31 papers). Gordon C. Jayson collaborates with scholars based in United Kingdom, United States and Canada. Gordon C. Jayson's co-authors include Jonathan A. Ledermann, Henry C Kitchener, Alan Jackson, Elise C. Kohn, Geoff J.M. Parker, James P.B. O’Connor, Lee M. Ellis, Adrian L. Harris, Robert S. Kerbel and Caleb Roberts and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Gordon C. Jayson

253 papers receiving 13.7k citations

Hit Papers

Ovarian cancer 2003 2026 2010 2018 2014 2015 2003 2016 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ovarian cancer
    2014 1.4k citations Gordon C. Jayson, Jonathan A. Ledermann et al. profile →
  2. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    2015 945 citations Sean Kehoe, Matthew Nankivell et al. profile →
  3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    2003 885 citations Mahesh Parmar, Jonathan A. Ledermann et al. profile →
  4. Antiangiogenic therapy in oncology: current status and future directions
    2016 644 citations Gordon C. Jayson, Adrian L. Harris et al. profile →
  5. Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI
    2006 524 citations Geoff J.M. Parker, Caleb Roberts et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gordon C. Jayson United Kingdom 56 4.7k 4.1k 4.1k 2.5k 2.2k 257 14.0k
Gordon Rustin United Kingdom 67 4.0k 0.9× 5.1k 1.2× 5.3k 1.3× 2.5k 1.0× 3.4k 1.6× 245 16.0k
Gabriella Ferrandina Italy 63 4.6k 1.0× 5.7k 1.4× 4.8k 1.2× 825 0.3× 3.4k 1.6× 496 15.8k
Christian Marth Austria 61 5.8k 1.2× 3.1k 0.8× 5.3k 1.3× 741 0.3× 1.6k 0.7× 411 14.0k
Andrew Berchuck United States 73 8.1k 1.7× 6.9k 1.7× 5.8k 1.4× 934 0.4× 1.6k 0.8× 358 19.9k
Beth Y. Karlan United States 69 8.0k 1.7× 6.6k 1.6× 6.4k 1.6× 651 0.3× 1.7k 0.8× 336 18.9k
Jalid Sehouli Germany 65 5.8k 1.2× 7.8k 1.9× 5.9k 1.4× 800 0.3× 4.3k 2.0× 866 19.2k
Gunnar B. Kristensen Norway 59 3.6k 0.8× 7.6k 1.8× 4.3k 1.0× 730 0.3× 3.8k 1.7× 266 14.7k
Hiroaki Kajiyama Japan 50 3.2k 0.7× 2.1k 0.5× 2.4k 0.6× 2.4k 1.0× 920 0.4× 423 10.3k
Ross S. Berkowitz United States 66 4.6k 1.0× 5.4k 1.3× 2.7k 0.7× 558 0.2× 2.4k 1.1× 445 18.7k
Rainer Kimmig Germany 52 2.2k 0.5× 3.6k 0.9× 3.6k 0.9× 862 0.3× 1.5k 0.7× 402 10.3k

Countries citing papers authored by Gordon C. Jayson

Since Specialization
Citations

This map shows the geographic impact of Gordon C. Jayson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon C. Jayson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon C. Jayson more than expected).

Fields of papers citing papers by Gordon C. Jayson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon C. Jayson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon C. Jayson. The network helps show where Gordon C. Jayson may publish in the future.

Co-authorship network of co-authors of Gordon C. Jayson

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon C. Jayson. A scholar is included among the top collaborators of Gordon C. Jayson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon C. Jayson. Gordon C. Jayson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sowerbutts, Anne Marie, Jana Sremanakova, Andrew R. Clamp, et al.. (2020). Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition. Journal of Human Nutrition and Dietetics. 33(4). 550–556. 9 indexed citations
3.
Vergote, Ignace, Corneel Coens, Matthew Nankivell, et al.. (2019). Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. Obstetrical & Gynecological Survey. 74(3). 156–158. 30 indexed citations
4.
5.
Conway, Alicia‐Marie, et al.. (2014). Accessing cancer services in North West England: the Chinese population. European Journal of Cancer Care. 23(4). 570–581. 2 indexed citations
6.
Jayson, Gordon C., Gavin J. Miller, Steen U. Hansen, et al.. (2014). The development of anti-angiogenic heparan sulfate oligosaccharides. Biochemical Society Transactions. 42(6). 1596–1600. 8 indexed citations
7.
Backen, Alison, Andrew G. Renehan, Andrew R. Clamp, et al.. (2014). The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. Clinical Cancer Research. 20(17). 4549–4558. 52 indexed citations
8.
Collinson, Fiona, Rachel A. Craven, David A. Cairns, et al.. (2013). Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. Clinical Cancer Research. 19(18). 5227–5239. 58 indexed citations
9.
Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations
10.
Mitchell, Claire L., James P.B. O’Connor, Caleb Roberts, et al.. (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemotherapy and Pharmacology. 68(3). 631–641. 19 indexed citations
11.
Mills, Samantha J., James P.B. O’Connor, G. Buonaccorsi, et al.. (2007). Quantifying Heterogeneity in Dynamic Contrast-Enhanced MRI Parameter Maps. Lecture notes in computer science. 10(Pt 2). 376–384. 16 indexed citations
12.
Brenchley, Paul, et al.. (2007). Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Science. 98(6). 844–849. 18 indexed citations
13.
Clamp, Andrew R., Fiona Blackhall, Gordon C. Jayson, et al.. (2006). The Morphogenic Properties of Oligomeric Endostatin Are Dependent on Cell Surface Heparan Sulfate. Journal of Biological Chemistry. 281(21). 14813–14822. 8 indexed citations
14.
15.
Jayson, Gordon C., Saifee Mullamitha, M.I. Saunders, et al.. (2005). Blockade of PDGF receptor beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and increased tumor vascularised volume. Journal of Clinical Oncology. 973–981. 1 indexed citations
16.
Tarrier, Nicholas, et al.. (2004). Psychological Morbidity after Chemotherapy in Ovarian Cancer. British Journal of Health Psychology. 9.
17.
Javaherian, Kashi, et al.. (2003). Binding of Endostatin to Endothelial Heparan Sulphate Shows a Differential Requirement for Specific Sulphates. Journal of Biological Chemistry. 1 indexed citations
18.
Shanks, J H, C. H. Buckley, W. David J. Ryder, et al.. (2000). Requirement for expert histopathological assessment of ovarian cancer and borderline tumours. British Journal of Cancer. 82(4). 760–762. 11 indexed citations
19.
Wardley, Andrew, et al.. (1998). The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. British Journal of Cancer. 78(6). 774–776. 27 indexed citations
20.
Jayson, Gordon C., et al.. (1994). Carcinomatous meningitis in breast cancer: An aggressive disease variant. Cancer. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gordon Rustin Breakdown of academic impact, for papers by Gabriella Ferrandina Breakdown of academic impact, for papers by Christian Marth Breakdown of academic impact, for papers by Andrew Berchuck Breakdown of academic impact, for papers by Beth Y. Karlan Breakdown of academic impact, for papers by Jalid Sehouli Breakdown of academic impact, for papers by Gunnar B. Kristensen Breakdown of academic impact, for papers by Hiroaki Kajiyama Breakdown of academic impact, for papers by Ross S. Berkowitz Breakdown of academic impact, for papers by Rainer Kimmig
Rankless by CCL
2026